Creative Medical Technology Holdings, Inc. (CELZ)
| Market Cap | 7.32M -11.8% |
| Revenue (ttm) | 3,000 -50.0% |
| Net Income | -6.04M |
| EPS | -1.95 |
| Shares Out | 6.59M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151,237 |
| Open | 1.060 |
| Previous Close | 1.060 |
| Day's Range | 1.060 - 1.120 |
| 52-Week Range | 0.620 - 6.250 |
| Beta | 2.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 7, 2026 |
About CELZ
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1... [Read more]
Financial Performance
In 2025, CELZ's revenue was $6,000, a decrease of -45.45% compared to the previous year's $11,000. Losses were -$6.00 million, 9.13% more than in 2024.
Financial StatementsNews
Roth believes Creative Medical’s ADAPT trial in CLBO ‘likely to succeed’
Roth Capital analyst Jonathan Aschoff maintained a Buy rating and $20 price target on Creative Medical (CELZ), noting that the company’s ADAPT trial evaluating CELZ-201, the company’s perinatal tissue...
Creative Medical completes enrollment in ADAPT clinical trial
Creative Medical (CELZ) announced that all patients have now been enrolled and treated across the company’s entire FDA-cleared ADAPT clinical trial evaluating CELZ-201 / Olastrocel, including the orig...
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
All patients enrolled and treated across original and FDA-cleared expansion cohorts Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chr...
Creative Medical receives notice of allowance for new U.S. patent
Creative Medical (CELZ) announced that it has received a notice of allowance from the United States Patent and Trademark Office, or USPTO, for a U.S. patent application titled “Suppression of…
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
Newly Allowed Patent Protects Cell-Free MyeloCelz™ Exosome Technology Designed to Suppress Autoimmune Destruction of Insulin-Producing Cells, Reinforcing Creative Medical's Multi-Program Diabetes Stra...
Creative Medical files to sell 5.58M shares of common stock for holders
16:07 EDT Creative Medical (CELZ) files to sell 5.58M shares of common stock for holders
Creative Medical Technology Holdings Issues Mid-Year Update
Highlights Significant Clinical, Regulatory, and Strategic Progress, Supported by a Disciplined Capital Allocation Strategy Highlights Significant Clinical, Regulatory, and Strategic Progress, Support...
Creative Medical announces agreements for exercise of warrants for $4.5M
Creative Medical (CELZ) Technology announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an…
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
PHOENIX, June 30, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a biotechnology company dedicated to the advancement of regenerative therapeutics...
Why Did Penny Stock Creative Medical Technology Holdings (CELZ) Rocket Higher Today?
Creative Medical Technology Holdings stock underwent a massive rally after the company withdrew public offering plans.
Creative Medical files to sell 3.05M shares of common stock
16:09 EDT Creative Medical (CELZ) files to sell 3.05M shares of common stock
Creative Medical expands ADAPT trial under new FDA clearance
Creative Medical (CELZ) announced that the FDA has cleared an expansion of the company’s FDA-cleared ADAPT clinical trial evaluating CELZ-201 for chronic lower back pain associated with degenerative d...
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
PHOENIX, June 22, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerativ...
Creative Medical launches national veteran data collection for Project PHOENIX
Creative Medical (CELZ) Technology announced the transition of Project PHOENIX, its proprietary veteran support registry and biodefense initiative, into its nationwide virtual data collection phase. D...
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
The regulatory approved CELZ-Biodefense platform is designed to scale to at least 1,000 veterans through AI-enabled mobile-app data collection and field-capable logistics
Creative Medical knee data ‘highly positive,’ says Roth Capital
Roth Capital analyst Jonathan Aschoff says Creative Medical (CELZ) this morning announced “highly positive” results from its pilot study of Ultrasome, a cell-free regenerative therapy for osteoarthrit...
Creative Medical reports pilot study of Ultrasome meets priamry endpoint
Creative Medical (CELZ) announced results from its pilot study of Ultrasome, the company’s cell-free regenerative therapy for the treatment of osteoarthritis of the knee. The study achieved its primar...
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market
Creative Medical achieves second WHO INN milestone
Creative Medical (CELZ) Technology Holdings announced the achievement of its second International Nonproprietary Name milestone with the World Health Organization, marking continued regulatory progres...
Creative Medical announces interim data from ADAPT trial of CELZ-201
Creative Medical (CELZ) Technology Holding announced interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201, the Company’s proprietary perinatal tissue-derived ce...
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile
Creative Medical receives regulatory approval for BioDefense Burn Pit Initiative
Creative Medical (CELZ) Technology announced that its BioDefense Burn Pit Initiative has received regulatory approval to proceed, marking a significant milestone in the Company’s mission to address th...
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerativ...
Creative Medical completes enrollment in ADAPT trial for CELZ-201
Creative Medical (CELZ) Technology announced the completion of patient enrollment in its FDA-cleared ADAPT clinical trial evaluating CELZ-201, the Company’s proprietary perinatal tissue-derived cell t...
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back Pain Completion of Enr...